$6.69 Billion is the total value of Avoro Capital Advisors LLC's 36 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARGX | ARGENX SEsponsored adr | $479,430,201 | +7.3% | 1,265,555 | 0.0% | 7.16% | -13.2% | |
| SRPT | SAREPTA THERAPEUTICS INC | $411,416,500 | +17.2% | 3,175,000 | 0.0% | 6.15% | -5.2% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $367,964,387 | +22.1% | 3,555,555 | 0.0% | 5.50% | -1.2% | |
| FOLD | AMICUS THERAPEUTICS INC | $327,228,000 | +17.0% | 26,800,000 | 0.0% | 4.89% | -5.4% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $262,603,250 | +18.7% | 1,105,000 | 0.0% | 3.92% | -4.0% | |
| XENE | XENON PHARMACEUTICALS INC | $193,207,000 | +9.2% | 4,900,000 | 0.0% | 2.89% | -11.7% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $103,894,000 | -8.9% | 9,050,000 | 0.0% | 1.55% | -26.3% | |
| CBAY | CYMABAY THERAPEUTICS INC | $64,581,000 | +79.1% | 10,300,000 | 0.0% | 0.96% | +44.9% | |
| MNKD | MANNKIND CORP | $47,957,000 | +70.6% | 9,100,000 | 0.0% | 0.72% | +38.2% | |
| MRSN | MERSANA THERAPEUTICS INC | $44,243,000 | -13.3% | 7,550,000 | 0.0% | 0.66% | -29.9% | |
| AADI BIOSCIENCES INC | $36,557,828 | -9.2% | 2,849,402 | 0.0% | 0.55% | -26.6% | ||
| RARE | ULTRAGENYX PHARMACEUTICAL INC | $34,747,500 | +11.9% | 750,000 | 0.0% | 0.52% | -9.6% | |
| PMVP | PMV PHARMACEUTICALS INC | $26,622,000 | -26.9% | 3,060,000 | 0.0% | 0.40% | -40.9% | |
| MARINUS PHARMACEUTICALS INC | $12,537,000 | -40.2% | 3,150,000 | 0.0% | 0.19% | -51.7% | ||
| FENC | FENNEC PHARMACEUTICALS INC | $11,520,000 | +18.5% | 1,200,000 | 0.0% | 0.17% | -4.4% | |
| IO BIOTECH INC | $4,728,531 | -15.1% | 2,055,883 | 0.0% | 0.07% | -31.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.